Drug Trial News

RSS

Diabetes medication shows promise in cutting migraine days by more than half

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.

20 Jun 2025

New clinical trial tests non-invasive method to protect hearts during chemotherapy

A simple intervention, similar to the tension applied to the arm during a blood pressure reading, is being tested in a Phase II clinical trial to see if it can help cancer patients treated with common chemotherapy drugs, called anthracyclines, avoid heart failure.

20 Jun 2025

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options.

18 Jun 2025

Combination therapy may improve health outcomes in adolescents with type 1 diabetes

A clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney disease and improve health outcomes.

17 Jun 2025

First patient treated in international clinical trial for rare muscle-weakness disease

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease known as Myasthenia Gravis.

16 Jun 2025

Two existing medications work effectively together in treating alcohol use disorder

Two existing medications - one used for smoking cessation and the other for depression - appear to work effectively together in treating alcohol use disorder.

16 Jun 2025

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

15 Jun 2025

Empagliflozin preserves kidney function in heart attack patients

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease.

13 Jun 2025

New drug combination shows high remission rates in acute myeloid leukemia

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide.

13 Jun 2025

New cancer vaccine shows promise against deadly pancreatic tumors

Pancreatic cancer has a five-year survival rate of just 13%, making it the deadliest cancer, according to the American Cancer Society.

11 Jun 2025

Weight loss drug semaglutide proven safe and effective for people with schizophrenia

Diabetic weight loss medications are effective for people with schizophrenia without affecting psychotic symptoms, University of Queensland researchers have found.

10 Jun 2025

Weekly risperidone capsule delivers consistent drug levels for schizophrenia patients

For many patients with schizophrenia, other psychiatric illnesses, or diseases such as hypertension and asthma, it can be difficult to take their medicine every day.

10 Jun 2025

Real-world study finds lower weight loss with GLP-1 drugs due to early discontinuation

A Cleveland Clinic study shows that semaglutide and tirzepatide – injectable GLP-1 drugs for obesity – produce smaller weight loss in a real-world setting because patients discontinue treatment or use lower maintenance dosages.

10 Jun 2025

Glioblastoma patients live longer with triple treatment strategy

A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a brain tumor diagnosis with few available effective treatments.

9 Jun 2025

Structured exercise strengthens immune response in cancer treatment

Exercising during chemotherapy and before surgery may help the body send more immune cells into cancerous tumors, according to a first-of-its-kind pilot study from the University of Surrey and Royal Surrey NHS Foundation Trust.

9 Jun 2025

DANTE trial reveals promising outcomes for shortened immunotherapy in advanced melanoma

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to breakthrough research led by the Universities of Sheffield and Leeds and Sheffield Teaching Hospitals NHS Foundation Trust.

5 Jun 2025

Nicotinamide riboside shows promise in treating Werner syndrome symptoms

Werner syndrome (WS) is a rare genetic disorder that causes premature aging and serious complications. In the first clinical trial of its kind, researchers from Japan with the company Niagen Bioscience, investigated the effects of nicotinamide riboside (NR), a vitamin B3 derivative, in patients with WS.

5 Jun 2025

New data shows zigakibart sustains proteinuria remission and kidney function in IgA nephropathy

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN).

5 Jun 2025

P2Y12 inhibitors linked to lower rates of cardiovascular events compared to aspirin

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, with no increased risk of major bleeding, finds a study published by The BMJ today.

5 Jun 2025

Type 2 diabetes drug shows improvements for patients with progressive liver disease

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published by The BMJ today.

5 Jun 2025

Drug Trial News

Diabetes medication shows promise in cutting migraine days by more than half

New clinical trial tests non-invasive method to protect hearts during chemotherapy

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

Combination therapy may improve health outcomes in adolescents with type 1 diabetes

First patient treated in international clinical trial for rare muscle-weakness disease

Two existing medications work effectively together in treating alcohol use disorder

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Empagliflozin preserves kidney function in heart attack patients

New drug combination shows high remission rates in acute myeloid leukemia

New cancer vaccine shows promise against deadly pancreatic tumors

Weight loss drug semaglutide proven safe and effective for people with schizophrenia

Weekly risperidone capsule delivers consistent drug levels for schizophrenia patients

Real-world study finds lower weight loss with GLP-1 drugs due to early discontinuation

Glioblastoma patients live longer with triple treatment strategy

Structured exercise strengthens immune response in cancer treatment

DANTE trial reveals promising outcomes for shortened immunotherapy in advanced melanoma

Nicotinamide riboside shows promise in treating Werner syndrome symptoms

New data shows zigakibart sustains proteinuria remission and kidney function in IgA nephropathy

P2Y12 inhibitors linked to lower rates of cardiovascular events compared to aspirin

Type 2 diabetes drug shows improvements for patients with progressive liver disease

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News